


The aim of the Fund is to achieve capital growth.
| Name | % Net Assets |
|---|---|
| Pfizer Inc. | 8.7% |
| Johnson & Johnson | 8.6% |
| Novartis AG | 7.1% |
| Roche Holding AG | 7.0% |
| Merck & Co. Inc. | 5.3% |
| Abbott Laboratories | 5.1% |
| GlaxoSmithKline PLC | 3.8% |
| Amgen Inc. | 3.2% |
| Bristol-Myers Squibb Co. | 3.2% |
| Essilor International S.A. | 3.1% |
| Key | % Net Assets |
|---|---|
| 8.7% | |
| 8.6% | |
| 7.1% | |
| 7.0% | |
| 68.6% |
| Date | n/a |
|---|---|
| Bid | 0.00 |
| Offer | 0.00 |
| Currency | n/a |
| Change | 0.00 |
| % | n/a |
| YTD change | 0.00 |
| YTD % | n/a |
| Fund Inception | 15/07/2002 |
|---|---|
| Fund Manager | Stephen Thornber |
| TER | - |
| Minimum Investment | |
|---|---|
| Initial | 500000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 1.00% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | -0.08 |
You are here: research